Scheduling delegate's final decisions. ACMS/ACCS, December 2015

Scheduling medicines and poisons

Book pagination

8 December 2015

1 Summary

Part A - Final decisions on matters referred to an expert advisory committee

1. Scheduling proposals referred to the August 2015 joint meeting of the Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (ACMS-ACCS#11)

Summary of delegate's final decisions
Substance Final Decision
METHYLISOTHIAZOLINONE

Schedule 6 - New Entry

METHYLISOTHIAZOLINONE in leave-on cosmetic products or therapeutic goods intended for leave-on topical application, except in preparations containing 0.01 per cent or less of methylisothiazolinone.

Appendix F, Part 3 - New Entry

METHYLISOTHIAZOLINONE

Warning Statement: 28

Safety Direction: (over)(repeated) exposure may cause sensitisation

Implementation date: 1 June 2016.

Schedule 6 - Amend Entry

METHYLISOTHIAZOLINONE except:

  1. In rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.01 per cent or less of methylisothiazolinone; or
  2. In other preparations that are not intended for direct application to the skin containing 0.1 per cent or less of methylisothiazolinone

Implementation date: 1 October 2017

METHYLCHLOROISOTHIAZOLINONE

Schedule 6 - New Entry

METHYLCHLOROISOTHIAZOLINONE in leave-on cosmetic products or therapeutic goods intended for leave-on topical application, except in preparations containing 0.0015 per cent or less of methylchloroisothiazolinone and methylisothiazolinone in total.

Appendix F, Part 3 - New Entry

METHYLCHLOROISOTHIAZOLINONE

Warning statement: 28

Safety Direction: (over)(repeated) exposure may cause sensitisation

Implementation date: 1 June 2016.

Schedule 6 - Amend Entry

METHYLCHLOROISOTHIAZOLINONE except:

  1. in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.0015 per cent or less of methylchloroisothiazolinone and methylisothiazolinone in total; or
  2. in other preparations that are not intended for direct application to the skin containing 0.1 per cent or less of methylchloroisothiazolinone and methylisothiazolinone in total.

Implementation date: 1 October 2017.

Book pagination